NCM · Biotechnology

Onconetix, Inc. (ONCO) Stock

$0.62 -5.24% NCM: ONCO Healthcare

Valuation

MetricValue
Price$0.62
Market Cap$2.22M
P/E Ratio-0.08
P/B Ratio0.12
P/S Ratio4.07
EPS (TTM)$-4.73
52-Week High$209.50
52-Week Low$0.59
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-91.95%
ROA-62.07%
ROCE-60.62%
Gross Margin-600.00%
Operating Margin-600.00%
Net Margin-13.20%
Debt/Equity0.01
Current Ratio0.67

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$3.0M$1.0M
Operating Profit$-3.0M$-13.0M$-36.0M$-56.0M$-6.0M
Net Profit$-3.0M$-13.0M$-37.0M$-59.0M$-14.0M
EPS$-0.09$-0.31$-25.03$-520.93$-4.73
Op Margin——-61634.5%-2238.0%-778.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$3.0M$26.0M$88.0M$28.0M$25.0M
Total Liabilities$2.0M$4.0M$86.0M$19.0M$9.0M
Cash$2.0M$26.0M$5.0M$1.0M$5.0M
Borrowings$0$0$10.0M$9.0M$0

Latest News

Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation GlobeNewswire · Jul 7, 2026 Onconetix Highlights Realbotix’s Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School District GlobeNewswire · Jun 24, 2026 BC-Most Active Stocks Associated Press · May 19, 2026 Onconetix, Inc. Announces 1-for-10 Reverse Stock Split GlobeNewswire · May 19, 2026 Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study GlobeNewswire · May 13, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-2.0M$-9.0M$-14.0M$-10.0M$-10.0M
Investing Cash Flow$0$0$-9.0M$0$0
Financing Cash Flow$0$-2.0M$0$0$0
Net Cash Flow$-2.0M$24.0M$-21.0M$-4.0M$5.0M
Free Cash Flow$-2.0M$-9.0M$-14.0M$-11.0M$-10.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.32
FCF Yield-391.97%
Quick Ratio2.14
Interest Coverage-26.28
Return 1Y-99.66%
Return 3Y-100.00%
Return 5Y—

Ownership

Insiders Held0.18%
Institutions Held0.06%
Institutions Float Held0.06%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AZTRAzitra Inc $0.13 -1.59% -0.10 $1.40M 0.00%
ENVBEnveric Biosciences, Inc. $1.45 -4.61% -0.09 $6.49M 0.00%
INDPIndaptus Therapeutics, Inc. $2.51 +5.91% -0.34 $284.24M 0.00%
JSPRJasper Therapeutics, Inc. $0.57 +1.82% -0.36 $9.27M 0.00%
PTIXProtagenic Therapeutics, Inc. $0.26 +18.18% -0.08 $470654 0.00%

About Onconetix, Inc.

Onconetix, Inc. is led by CEO David Allan White, employs 12 people, headquartered in US, publicly traded since 2022.

Onconetix, Inc. (ONCO) stock trades at $0.62 with a market capitalization of $2.22M. The stock is valued at a price-to-earnings (P/E) ratio of -0.08, price-to-book of 0.12, price-to-sales of 4.07. Over the past 52 weeks the stock has ranged between $0.59 and $209.50, and currently trades 99.7% below its 52-week high.

On profitability, Onconetix, Inc. generates a return on equity (ROE) of -91.95%, return on capital employed of -60.62%, an operating margin of -600.00%, a net profit margin of -13.20%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides